2021 World Conference on Lung Cancer (Posters)-FP12. PD-L1 Assessment in Cytology is Comparable to Histology in Predicting Treatment Response to Checkpoint Inhibitors in NSCLC

FP12. PD-L1 Assessment in Cytology is Comparable to Histology in Predicting Treatment Response to Checkpoint Inhibitors in NSCLC

Back to course

Video Transcription

Video Summary

The study investigated the use of PD-L1 assessment in cytology samples compared to histology samples in predicting treatment response to PD-L1 inhibitors in patients with advanced non-small cell lung cancer. The researchers reviewed cytology and histology samples from 2013 to 2020 and found that the success rates of PD-L1 testing and the distribution of PD-L1 expression were similar in both sample types. They also found that response rates and progression-free survival were comparable between cytology and histology samples, suggesting that biomarker testing on cytology samples is effective. The results support the use of cytology samples for PD-L1 assessment.

Asset Subtitle

Sally CM Lau

Meta Tag

Speaker Sally CM Lau

Topic Predictive Tumor Based Assays/ Biomarkers/ Pathology

Keywords

PD-L1 assessment

cytology samples

histology samples

treatment response

PD-L1 inhibitors